TW200815455A - Organic compounds - Google Patents

Organic compounds Download PDF

Info

Publication number
TW200815455A
TW200815455A TW096130206A TW96130206A TW200815455A TW 200815455 A TW200815455 A TW 200815455A TW 096130206 A TW096130206 A TW 096130206A TW 96130206 A TW96130206 A TW 96130206A TW 200815455 A TW200815455 A TW 200815455A
Authority
TW
Taiwan
Prior art keywords
epothilone
doc
disease
representative
treating
Prior art date
Application number
TW096130206A
Other languages
English (en)
Chinese (zh)
Inventor
Ernst Kusters
Michael Mutz
Frank Stowasser
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37685905&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW200815455(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of TW200815455A publication Critical patent/TW200815455A/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D493/00Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
TW096130206A 2006-08-16 2007-08-15 Organic compounds TW200815455A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119043 2006-08-16

Publications (1)

Publication Number Publication Date
TW200815455A true TW200815455A (en) 2008-04-01

Family

ID=37685905

Family Applications (1)

Application Number Title Priority Date Filing Date
TW096130206A TW200815455A (en) 2006-08-16 2007-08-15 Organic compounds

Country Status (22)

Country Link
US (1) US8178566B2 (https=)
EP (1) EP2064216A2 (https=)
JP (1) JP2010500387A (https=)
KR (1) KR20090038902A (https=)
CN (1) CN101506217B (https=)
AR (1) AR062375A1 (https=)
AU (1) AU2007286454A1 (https=)
BR (1) BRPI0715963A2 (https=)
CA (1) CA2658475A1 (https=)
CL (1) CL2007002362A1 (https=)
IL (1) IL196558A0 (https=)
MA (1) MA30656B1 (https=)
MX (1) MX2009001635A (https=)
MY (1) MY148355A (https=)
NO (1) NO20091081L (https=)
NZ (1) NZ574194A (https=)
PE (1) PE20081317A1 (https=)
RU (1) RU2009109352A (https=)
TN (1) TN2009000044A1 (https=)
TW (1) TW200815455A (https=)
WO (1) WO2008019820A2 (https=)
ZA (1) ZA200900227B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011255647A1 (en) 2010-05-18 2012-11-15 Cerulean Pharma Inc. Compositions and methods for treatment of autoimmune and other diseases
CN103910742B (zh) * 2013-01-07 2016-07-13 浙江海正药业股份有限公司 一种制备埃博霉素b无定形粉末的方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK287775B6 (sk) 1998-02-05 2011-09-05 Novartis Ag Farmaceutická formulácia obsahujúca epothilon, infúzny roztok a použitie farmaceutickej formulácie
US6194181B1 (en) * 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
GB0029895D0 (en) 2000-12-07 2001-01-24 Novartis Ag Organic compounds
BRPI0314133A8 (pt) * 2002-09-23 2017-09-19 Bristol Myers Squibb Co Processo para isolamento de epotilona b, métodos para cultivo de microorganismo que produza epotilona a ou b e para purifiação de apotilona

Also Published As

Publication number Publication date
KR20090038902A (ko) 2009-04-21
PE20081317A1 (es) 2008-10-28
NO20091081L (no) 2009-03-16
MA30656B1 (fr) 2009-08-03
TN2009000044A1 (en) 2010-08-19
IL196558A0 (en) 2009-11-18
AU2007286454A1 (en) 2008-02-21
CA2658475A1 (en) 2008-02-21
MY148355A (en) 2013-03-29
US8178566B2 (en) 2012-05-15
AR062375A1 (es) 2008-11-05
ZA200900227B (en) 2009-12-30
CL2007002362A1 (es) 2008-08-08
BRPI0715963A2 (pt) 2013-08-06
CN101506217B (zh) 2012-09-05
MX2009001635A (es) 2009-02-23
WO2008019820A2 (en) 2008-02-21
RU2009109352A (ru) 2010-09-27
WO2008019820A3 (en) 2008-04-17
US20100160393A1 (en) 2010-06-24
NZ574194A (en) 2011-12-22
CN101506217A (zh) 2009-08-12
EP2064216A2 (en) 2009-06-03
JP2010500387A (ja) 2010-01-07

Similar Documents

Publication Publication Date Title
TW457095B (en) Pharmaceutical formulations comprising epothilones and lyophilised compositions comprising epothilones
EP1797874B1 (en) Vascular embolus of paclitaxel-sodium alginate microsphere and its preparation
FR2775187A1 (fr) Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
EP3547999A1 (en) Calcium lactate compositions and methods of use
CN109745287A (zh) 非水性紫杉烷前-乳剂制剂以及制备和使用该制剂的方法
CN103788043B (zh) 硝克柳胺化合物晶iv型、其制法和其药物组合物与用途
CN105997942B (zh) 一种人血清白蛋白负载美登素类药物的纳米颗粒及其制备方法和应用
CA2900508C (en) Cabazitaxel composition
TW200815455A (en) Organic compounds
CA2627544A1 (en) Formulations of quinolinones for the treatment of cancer
JP2025011312A (ja) p-ボロノフェニルアラニンを含有する注射液剤の析出防止方法
CN115671107B (zh) 用于解酒的复方药物组合物
CN113456643B (zh) 一种含普那布林的药物组合及其应用
JP7105465B2 (ja) キニーネ塩懸濁液を含む抗癌治療のための局所投与用注射剤組成物及び懸濁液注射剤の製造方法
RU2195937C1 (ru) Комбинированный противотуберкулезный препарат (ризобутол)
KR20250013306A (ko) 페오놀 및 아포시닌을 포함하는 액체 제형
TW201235038A (en) Sensitizer, kit and use for cancer therapy
CN101185629A (zh) 一种治疗实体肿瘤的地西他滨缓释剂
CN114099703A (zh) 一种简便制备的青蒿素类抗癌纳米前药、其制备方法及应用
CN103054881B (zh) 治疗肺癌的中药活性成分复方制剂及其制备方法
JP2833821B2 (ja) 抗癌剤
JP2010500387A5 (https=)
Pedro Formulações à Base de Solventes Eutécticos Profundos para o Desenvolvimento de Sistemas de Administração de Fármacos
HK40103513A (zh) 包含乳酸钙的药物组合物及其用途
WO2023016495A1 (zh) 含有白果内酯和大麻二酚的药物组合物及其在医药上的应用